Related Experiment Video

Updated: May 30, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Antineoplastic action of growth hormone-releasing hormone (GHRH) antagonists

Agnieszka Siejka1, Hanna Lawnicka, Gabriela Melen-Mucha

  • 1Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Dr. Sterling 3 Str., 91-425, Lodz, Poland.

Recent Patents on Anti-Cancer Drug Discovery
|August 23, 2011
PubMed

Insights

Growth hormone-releasing hormone (GHRH) antagonists show promise in inhibiting human cancer growth. Newer antagonists target tumors directly, reducing side effects associated with growth hormone deficiency.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Growth hormone-releasing hormone (GHRH) antagonists can inhibit experimental human cancers.
  • Initial GHRH antagonists primarily worked by reducing growth hormone (GH) and insulin-like growth factor (IGF)-1 levels.
  • This indirect mechanism has limitations due to potential growth hormone deficiency complications.

Purpose of the Study:

  • To review recent advancements in GHRH antagonists for cancer therapy.
  • To highlight novel antagonists with direct antitumor effects.
  • To discuss the potential clinical applications of these agents in oncology.

Main Methods:

  • Review of recent patents and scientific literature.
  • Analysis of GHRH antagonist mechanisms of action.
  • Focus on direct tumor-targeting strategies versus endocrine effects.

Main Results:

  • GHRH antagonists can inhibit various human cancer types.
  • Newer GHRH antagonists exhibit potent direct antitumor activity.
  • These agents act via receptor-mediated pathways affecting intracellular signaling in tumors.
  • Tumorigenesis-related signaling pathways are implicated.

Conclusions:

  • GHRH antagonists represent a promising therapeutic strategy for human cancers.
  • Directly targeting GHRH receptors on cancer cells offers a more focused approach.
  • Further research into receptor-mediated mechanisms could unlock new clinical applications.

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.